{
    "root": "ba25ec4f-3b81-4960-bf74-6a1e4c6be45c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Hydromorphone Hydrochloride",
    "value": "20231215",
    "ingredients": [
        {
            "name": "HYDROMORPHONE HYDROCHLORIDE",
            "code": "L960UP2KRW",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5791"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "hydromorphone hydrochloride injection indicated management pain severe enough require opioid analgesic alternative treatments inadequate . limitations risks addiction , abuse , misuse opioids , occur duration [ ( 5.1 ) ] , reserve hydromorphone hydrochloride injection patients alternative treatment options ( e.g . , non-opioid analgesics opioid combination products ) : tolerated expected tolerated provided adequate analgesia expected provide adequate analgesia hydromorphone hydrochloride injection used extended period time unless pain remains severe enough require opioid analgesic alternative treatment options continue inadequate .",
        "doid_entities": [
            {
                "text": "analgesia (DOID:0060145)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060145"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "hydromorphone hydrochloride injection prescribed healthcare professionals knowledgeable opioids mitigate associated risks . ( 2.1 ) lowest effective shortest duration consistent individual patient treatment goals . reserve titration higher doses hydromorphone hydrochloride injection patients lower doses insufficiently effective expected benefits using higher dose opioid clearly outweigh substantial risks . ( 2.1 , 5 ) many acute pain conditions ( e.g . , pain occurs number surgical procedures acute musculoskeletal injuries ) require days opioid analgesic . guidelines opioid prescribing acute pain conditions available . ( 2.1 ) initiate dosing regimen patient individually , taking account patient \u2019 underlying cause severity pain , prior analgesic treatment response , risk factors addiction , abuse , misuse . ( 2.1 , 5.1 ) respiratory depression occur time opioid therapy , especially initiating following increases hydromorphone hydrochloride injection . consider risk selecting initial dose making dose adjustments . ( 2.1 , 5.2 ) initial : - intramuscular subcutaneous : usual starting dose 1 mg 2 mg every 2 3 hours necessary . ( 2.2 ) - intravenous : usual starting dose 0.2 mg 1 mg every 2 3 hours . injection given slowly , least 2 3 minutes . ( 2.2 ) hepatic impairment : initiate treatment one-fourth one-half usual starting dose , depending degree hepatic impairment . ( 2.3 ) renal impairment : initiate treatment one-fourth one-half usual starting dose , depending degree renal impairment . ( 2.4 ) abruptly discontinue hydromorphone hydrochloride injection physically-dependent patient . ( 2.6 , 5.12 )",
        "doid_entities": [
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute musculoskeletal injuries",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2674"
            },
            {
                "disease": "acute pain conditions",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_454831"
            }
        ]
    },
    "warningsAndPrecautions": "hydromorphone hydrochloride injection clear , colorless , sterile , aqueous solution available multi-dose clear glass vial containing 40 mg/20 ml ( 2 mg/ml ) . supplied following packaging configuration : carton containing 1 multi-dose vial : ndc 0641-6254-01 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "hydromorphone hydrochloride injection contraindicated patients : \u2022 significant respiratory depression [ ( 5.2 ) ] \u2022 acute severe bronchial asthma unmonitored setting absence resuscitative equipment [ ( 5.2 ) ] \u2022 known suspected gastrointestinal obstruction , including paralytic ileus [ ( 5.10 ) ] \u2022 hypersensitivity hydromorphone , hydromorphone salts , components product .",
    "indications_original": "Hydromorphone Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. \n                  \n                     Limitations of Use\n                  \n                  Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.1)], reserve Hydromorphone Hydrochloride Injection for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): \n                  \n                     Have not been tolerated or are not expected to be tolerated\n                     Have not provided adequate analgesia or are not expected to provide adequate analgesia\n                  \n                  Hydromorphone Hydrochloride Injection should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.",
    "contraindications_original": "Hydromorphone Hydrochloride Injection should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. ( 2.1 ) Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. Reserve titration to higher doses of Hydromorphone Hydrochloride Injection for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. ( 2.1 , 5 ) Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available. ( 2.1 ) Initiate the dosing regimen for each patient individually, taking into account the patient\u2019s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse. ( 2.1 , 5.1 ) Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with Hydromorphone Hydrochloride Injection. Consider this risk when selecting an initial dose and when making dose adjustments. ( 2.1 , 5.2 ) Initial Dosage: - Intramuscular or Subcutaneous Use: The usual starting dose is 1 mg to 2 mg every 2 to 3 hours as necessary. ( 2.2 ) - Intravenous Use : The usual starting dose is 0.2 mg to 1 mg every 2 to 3 hours. The injection should be given slowly, over at least 2 to 3 minutes. ( 2.2 ) Hepatic Impairment: Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of hepatic impairment. ( 2.3 ) Renal Impairment : Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of renal impairment. ( 2.4 ) Do not abruptly discontinue Hydromorphone Hydrochloride Injection in a physically-dependent patient. ( 2.6 , 5.12 )",
    "warningsAndPrecautions_original": "Hydromorphone Hydrochloride Injection is a clear, colorless, sterile, aqueous solution available in multi-dose clear glass vial containing 40 mg/20 mL (2 mg/mL). It is supplied in the following packaging configuration:\n                  \n                     Carton containing 1 multi-dose vial: NDC 0641-6254-01 \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions_original": "Hydromorphone Hydrochloride Injection is contraindicated in patients with: \n                  \u2022 Significant respiratory depression [see Warnings and Precautions (5.2)]\n                  \n                  \n                     \u00a0\u2022 Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.2)]\n                  \n                  \n                     \u00a0\u2022 Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.10)]\n                  \n                  \n                     \u00a0\u2022 Hypersensitivity to hydromorphone, hydromorphone salts, any other components of the product.",
    "drug": [
        {
            "name": "Hydromorphone Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5791"
        }
    ]
}